Therefore, incorporating β2M into established prognostic models, such as the NCCN‐IPI, is recommended to improve risk stratification accuracy and enhance the predictive validity of outcomes in DLBCL patients. This evidence concerns the gene B2M and diffuse large B-cell lymphoma.